159 related articles for article (PubMed ID: 34990529)
1. Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review.
Geurts SME; Aarts AMWM; Verbeek ALM; Chen THH; Broeders MJM; Duffy SW
Epidemiol Health; 2022; 44():e2022008. PubMed ID: 34990529
[TBL] [Abstract][Full Text] [Related]
2. Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer.
Aarts AMWM; Duffy SW; Geurts SME; Vulkan DP; Houssami N; Zappa M; Nagtegaal ID; Verbeek ALM; Broeders MJM
Breast; 2019 Jun; 45():70-74. PubMed ID: 30884341
[TBL] [Abstract][Full Text] [Related]
3. Bayesian evaluation of breast cancer screening using data from two studies.
Myles JP; Nixon RM; Duffy SW; Tabar L; Boggis C; Evans G; Shenton A; Howell A
Stat Med; 2003 May; 22(10):1661-74. PubMed ID: 12720303
[TBL] [Abstract][Full Text] [Related]
4. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
5. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase.
Duffy SW; Chen HH; Tabar L; Day NE
Stat Med; 1995 Jul; 14(14):1531-43. PubMed ID: 7481190
[TBL] [Abstract][Full Text] [Related]
6. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.
Prevost TC; Launoy G; Duffy SW; Chen HH
Am J Epidemiol; 1998 Sep; 148(6):609-19. PubMed ID: 9753016
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Length of the Preclinical Detectable Phase for Open-Angle Glaucoma.
Aspberg J; Heijl A; Bengtsson B
JAMA Ophthalmol; 2023 Jan; 141(1):48-54. PubMed ID: 36416831
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.
Launoy G; Smith TC; Duffy SW; Bouvier V
Int J Cancer; 1997 Oct; 73(2):220-4. PubMed ID: 9335446
[TBL] [Abstract][Full Text] [Related]
9. Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data.
Weedon-Fekjær H; Li X; Lee S
J Med Screen; 2021 Sep; 28(3):302-310. PubMed ID: 32854582
[TBL] [Abstract][Full Text] [Related]
10. Cancer screening estimates for U.S. metropolitan areas.
Nelson DE; Bolen J; Marcus S; Wells HE; Meissner H
Am J Prev Med; 2003 May; 24(4):301-9. PubMed ID: 12726867
[TBL] [Abstract][Full Text] [Related]
11. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.
Lee SJ; Boscardin WJ; Stijacic-Cenzer I; Conell-Price J; O'Brien S; Walter LC
BMJ; 2013 Jan; 346():e8441. PubMed ID: 23299842
[TBL] [Abstract][Full Text] [Related]
12. Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results.
Weedon-Fekjaer H; Vatten LJ; Aalen OO; Lindqvist B; Tretli S
J Med Screen; 2005; 12(4):172-8. PubMed ID: 16417693
[TBL] [Abstract][Full Text] [Related]
13. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations.
Shen Y; Zelen M
J Clin Oncol; 2001 Aug; 19(15):3490-9. PubMed ID: 11481355
[TBL] [Abstract][Full Text] [Related]
14. Test sensitivity of mammography and mean sojourn time over 40 years of breast cancer screening in Nijmegen (The Netherlands).
Aarts A; Duffy SW; Geurts S; Vulkan DP; Otten J; Hsu CY; Chen T; Verbeek A; Broeders M
J Med Screen; 2019 Sep; 26(3):147-153. PubMed ID: 30541383
[No Abstract] [Full Text] [Related]
15. MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.
Wu D; Rosner GL; Broemeling L
Biometrics; 2005 Dec; 61(4):1056-63. PubMed ID: 16401279
[TBL] [Abstract][Full Text] [Related]
16. Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors.
Hsu CY; Yen MF; Auvinen A; Chiu YH; Chen HH
Stat Methods Med Res; 2018 Aug; 27(8):2519-2539. PubMed ID: 29984633
[TBL] [Abstract][Full Text] [Related]
17. Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data.
Chen Y; Brock G; Wu D
Cancer Epidemiol; 2010 Aug; 34(4):429-33. PubMed ID: 20434974
[TBL] [Abstract][Full Text] [Related]
18. Screening for colorectal cancer: current status in Japan.
Saito H
Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
[TBL] [Abstract][Full Text] [Related]
19. Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
Walpole E; Dunn N; Youl P; Harden H; Furnival C; Moore J; Taylor K; Evans E; Philpot S
Int J Cancer; 2020 Aug; 147(3):856-865. PubMed ID: 31808149
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
